Source: Leukemia & lymphoma. Unidade: FM
Subjects: LINFOMA, SOBREVIDA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROBAK, Tadeusz et al. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*). Leukemia & lymphoma, v. 60, n. 1, p. 172-179, 2019Tradução . . Disponível em: https://doi.org/10.1080/10428194.2017.1321750. Acesso em: 11 out. 2024.APA
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., et al. (2019). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*). Leukemia & lymphoma, 60( 1), 172-179. doi:10.1080/10428194.2017.1321750NLM
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) [Internet]. Leukemia & lymphoma. 2019 ; 60( 1): 172-179.[citado 2024 out. 11 ] Available from: https://doi.org/10.1080/10428194.2017.1321750Vancouver
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) [Internet]. Leukemia & lymphoma. 2019 ; 60( 1): 172-179.[citado 2024 out. 11 ] Available from: https://doi.org/10.1080/10428194.2017.1321750
